Immunotherapy with anti-PD-1/PD-L1 agents either as single agents or combined with
chemotherapy is now considered the standard of care for patients with non-small-cell lung
cancer. However, it has not been incorporated in the Brazilian Public Health System because
of concerns about patient eligibility, safety and costs. It is known that simple biomarkers
can be used to select patients for immunotherapy, such as EGRF, ALK and PD-L1 status in the
tumors. We created a treatment protocol based on these 3 markers and treated 154 patients
with non-small-cell-lung cancer in a Public Hospital in Brazil. The goal of this project is
to identify the prevalence of these markers in the Brazilian population (to estimate patient
eligibility), outcomes and costs of therapy.